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Background
Medical ghostwriting, the practice of
pharmaceutical companies secretly au-
thoring journal articles published under
the byline of academic researchers, is a
troubling phenomenon because it is dan-
gerous to public health [1]. For example,
ghostwritten articles on rofecoxib [2]
probably contributed to ‘‘…lasting injury
and even deaths as a result of prescribers
and patients being misinformed about
risks’’ [3]. Study 329, a randomized
controlled trial of paroxetine in adoles-
cents, was ghostwritten [4–7] to claim that
paroxetine is ‘‘generally well tolerated and
effective for major depression in adoles-
cents’’ [8], although data made available
through legal proceedings show that
‘‘Study 329 was negative for efficacy on
all 8 protocol specified outcomes and
positive for harm’’ [9]. Even beyond frank
misrepresentation of data, commercially
driven ghostwritten articles shape the
medical literature in subtler but important
ways, affecting how health conditions and
treatments are perceived by clinicians.
The ability of industry to exercise clan-
destine influence over the peer-reviewed
medical literature is thus a serious threat to
public health [1,10].
In 2009, the Institute of Medicine
recommended that US-based academic
medical centers enact policies that prohibit
ghostwriting by their faculties [11]. How-
ever, to date, there has been no systematic
assessment of ghostwriting policies at
academic medical centers. Since US-based
academic medical centers generate bio-
medical research for a worldwide audi-
ence, we chose to conduct the first such
investigation on elite US-based academic
medical centers. Our methods are shown
in Box 1. We sought to describe the
current policy situation at US-based aca-
demic centers and then to propose an ideal
ghostwriting policy.
Findings of Our Survey
Of the 50 academic medical centers that
we examined (Box 1), ten (20%) explicitly
prohibit ghostwriting. Of these ten, seven
(14%) include some definition of ghost-
writing in their policy, while three (6%)
prohibit ghostwriting without defining the
term. Many schools have an authorship
policy that does not clearly ban all aspects
of ghostwriting (n=13, 26%); the most
common reason is a failure to require that
all qualified authors be listed. Three
academic medical centers (6%) have
stringent authorship policies that prohibit
it in practice (by requiring both a substan-
tive contribution to qualify for authorship
and that all who qualify for authorship be
listed) but do not mention ghostwriting by
name (Table 1).
By combining the ten schools that
explicitly ban ghostwriting with the three
schools that have authorship policies
banning it in practice, we find that 13 of
the top-50 academic medical centers
(26%) have policies in place prohibiting
medical ghostwriting. Six of the top-ten
schools ban ghostwriting in practice, and
all top-ten academic medical centers have
published authorship policies. Although
most schools (n=45, 90%) had some
policy documents posted online, the ma-
jority of academic medical centers (n=26,
52%) had no published policies at all on
either ghostwriting or authorship. The
Web sites of two schools stated that they
did have such policies, but the policies
were not currently available online.
Implications of These Findings
A minority of top-50 US-based aca-
demic medical centers (n=13, 26%) pub-
licly prohibit their faculty from participat-
ing in ghostwriting. It is ironic that
ghostwriting, a major threat to public
health, is generally not prohibited within
institutions that exist to train physicians
and improve the public health. In this
way, academic medical centers enable the
pharmaceutical industry to covertly shape
the medical literature in favor of commer-
cial interests. When a pharmaceutical
salesperson hands a clinician an article
reprint, the name of the institution on the
front page of the reprint serves as a stamp
of approval. The article is not viewed as an
advertisement, but as scientific research;
the reprint is an effective marketing tool
because peer-reviewed journal articles
generated in academia are perceived to
be the result of unbiased scientific inquiry.
Deception regarding authorship prevents
a discriminating audience from properly
assessing the impact of bias in the
published article [10]. Importantly, this
deception is impossible without the coop-
eration of faculty employed by academic
medical centers.
The practice of ghostwriting explicitly
violates the usual norms of academia. We
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where it is acceptable for professors to
allow themselves to be listed as authors on
research papers they did not write, or to
purposefully conceal the contributions of
industry coauthors in order to mislead
readers. A recent New York Times article
characterizes medical ghostwriting as ‘‘an
academic crime akin to plagiarism’’ [12].
Anecdotally, we find many of our aca-
demic colleagues are stunned to hear
about ghostwriting in medical schools,
and some of our graduate students express
dismay. (They have to write their own
papers, and face disciplinary action and
even expulsion if they submit term papers
they did not write). In contrast, academic
medical centers in the US and Europe
employ professors who are publicly known
to have participated in ghostwriting (e.g.,
[4–6,13]). The culture of biomedical
research apparently condones or at best
takes a neutral position when it comes to
ghostwriting. This suggests that ghostwrit-
ing will continue to be a problem until
policy solutions are implemented. While
our survey examined only published
policies, the dearth of such policies is
cause for concern.
Perhaps ghostwriting policies should be
examined in the context of existing policies
meant to regulate ethical research behav-
ior. It is possible that some academic
medical centers already prohibit ghost-
writing under other rules of research
integrity. For instance, ghostwriting may
be characterized as a form of plagiarism
[14], and to our knowledge, all academic
institutions consider plagiarism to be a
form of academic misconduct. Some
academics have listed ghostwritten publi-
cations on their curricula vitae, meaning
that they were considered for promotion
and/or grants on the basis of fraudulent
authorship, which would seem to be
grounds for disciplinary action. It has
been reported that academics receive
payments from industry for participation
in ghostwriting, and many institutions
have rules requiring faculty to report
outside income. Failure to report such
income truthfully may violate existing
policies. In theory, an administrator could
penalize a violation of such policies by a
faculty member who has participated in
ghostwriting. If any of this has ever
occurred, it is not publicly known.
A policy is only as useful as it is
enforceable. A policy prohibiting ghost-
writing that cannot be effectively enforced
is unlikely to change practice. It is worth
considering, then, whether existing policies
of academic medical centers regulating
authorship and ghostwriting clearly define
‘‘ghostwriting’’? Is a policy useful if it
forbids ghostwriting but never defines the
term? Can we envision an academic being
sanctioned for violating a policy that does
not define its critical terms? Or does this
lack of clarity provide ‘‘wiggle room’’ to
evade sanctions? Our review of existing
ghostwriting policies (see Datasets S1
and S2) indicates that the clarity of many
policies could be improved substantially.
For instance, the New York Times reported
that Duke University has a policy which
bans ghostwriting [15]. On closer exami-
nation, what Duke’s policy prohibits is
courtesy authorship—but it does not
require that all contributors who qualify
as authors be listed as such. The policy
requires that a substantial contribution be
made to qualify for authorship, but does
not prohibit the concealment of corporate
Box 1. Methods
At the beginning of the 2009–2010 academic year, we evaluated the policies of
the top-50 academic medical centers by research ranking according to the 2009
US News and World Report [29]. To avoid response bias, and given that faculty
policies are commonly published on the World Wide Web, we searched for
publicly available policy documents. We used a standardized search protocol in
the Google search engine and key phrases used in policies regulating authorship,
ghostwriting, and conflicts of interest. When we were unable to locate a
published authorship policy, we contacted a reference librarian at the institution
to verify that no policy was available. We also searched each Web site to see if any
conflict-of-interest policies or faculty manuals were available on-line. We retrieved
only policies that were publicly available and applicable to the entire academic
medical center. Our retrieval method removed social desirability bias as a possible
confounder but was time-intensive, leading us to examine only the top-50
schools, a trade-off we found reasonable given the influential nature of elite US-
based medical schools in the worldwide biomedical research community and the
exploratory nature of this research.
One rater (JRL) extracted data from the policies. If an academic medical center
explicitly prohibited ghostwriting, this was coded as such, and the policy was
transcribed. If ghostwriting was not mentioned, but there was an authorship
policy, the policy was coded on whether it mandated (1) a substantive
contribution to qualify for authorship and (2) that all individuals who make
substantial contributions to the manuscript be listed as authors. Inclusion of both
(1) and (2) was coded as prohibiting ghostwriting in practice.
To ensure reliability, two sets of data were blindly recoded by the second author
(JL). First, a 50% random sample of those medical centers coded as lacking any
authorship policies was recoded. There was disagreement on the existence of an
authorship policy at one institution, which was resolved through discussion.
Second, a 50% random sample of institutions with authorship policies were
recoded on the two primary variables of interest, with perfect agreement
between the two raters. All data are available as an Excel spreadsheet file, which
includes hyperlinks to each institution’s policies (Dataset S1), or as a PDF file
(Dataset S2).
Table 1. Published policies of academic medical centers meeting specific criteria
(n=50).
Criteria n %
Some faculty policies available on-line 45 90
Ghostwriting explicitly banned 10 20
Ghostwriting explicitly banned and defined in some way 7 14
Authorship policy that does not mention ghostwriting 13 26
Authorship policy requires substantial contribution for authorship 9 18
Authorship policy requires all those that qualify as authors must be listed as such 3 6
Policy that bans ghostwriting in practice 13 26
No published policy on either authorship or ghostwriting 26 52
doi:10.1371/journal.pmed.1000230.t001
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script. A professor could follow this
policy to the letter and still participate in
something most people would call ‘‘ghost-
writing’’ [16] by failing to list a corporate
coauthor in the author byline. Other




Ghostwriting was once the ‘‘dirty little
secret’’ of the medical literature [3], but
this no longer is the case. Pharmaceutical
companies have used ghostwriting to
market sertraline [17], olanzapine [18],
gabapentin [19], estrogen replacement
therapy [20], rofecoxib [2], paroxetine
[4,21], methylphenidate [22], milnaciprin
[23], venlafaxine [24], and dexfenflura-
mine [25]. Ghostwriting is now known to
be a major industry [26].
In the near future, we expect adminis-
trators of academic medical centers to
enact policies that regulate medical ghost-
writing. Such policies must be oper-
ationalized specifically enough to actually
change practice. A problematic policy may
be worse than no policy at all, as it may
give the misleading impression that the
ghostwriting problem has been solved.
Therefore, we make the following policy
proposal to academic medical centers
worldwide.
The Proposal
First, deans of academic medical centers
should immediately inform their faculties
that a ban on medical ghostwriting will be
enacted shortly. Following the suggestion
by Barton Moffatt and Carl Elliot [1], the
remaining months in the 2009–2010
academic year should be a period of
amnesty. Faculty who have participated
in ghostwriting will be allowed to come
forward and describe their involvement.
Known ghostwritten papers should be
reevaluated by the academic medical
community and considered for retraction.
Next, a policy that clearly defines
participation in ghostwriting as a form of
academic misconduct should be imple-
mented at the beginning of the 2010–2011
academic year. By modifying several
existing authorship policies to close any
loopholes and be as specific as possible, we
suggest the following wording:
‘‘All listed authors on a publication
must meet the authorship criteria set by
the International Committee of Medical
JournalEditors.Makingminorrevisionsto a
manuscript does not qualify as authorship.
Participating in the creation of ghost-
authored manuscripts is not permitted. A
ghost author is defined as someone who
makes substantial contributions to writing a
publication but is not listed as an author. All
individuals who have made a substantial
contribution to the manuscript must be
listed as authors. Accurately reporting
authorship is essential for maintaining
research integrity, and violating any of these
rules is considered research misconduct akin
to plagiarism or falsification of data.’’
Implementation and Enforcement
Government funding agencies can play
a primary role in encouraging the adop-
tion of this policy. Francis Collins, Direc-
tor of the US National Institutes of Health
(NIH), recently remarked that ‘‘I was
shocked by that revelation—that people
would allow their names to be used on
articles they did not write, that were
written for them, particularly by compa-
nies that have something to gain by the
way the data is presented…if we want to
have the integrity of science preserved—
that’s not the way to do it’’ [27]. We agree,
and suggest that, to encourage the adop-
tion of this policy, NIH and similar
funding agencies should refuse to disperse
any public research funds to institutions
that do not adopt a policy which bans
ghostwriting, as we have suggested above.
Academic medical centers are funded with
public monies because they ostensibly
serve the public good. Since ghostwriting
harms public health and serves commer-
cial rather than public interests, govern-
ments should not support institutions that
permit ghostwriting.
At the institutional level, vigorous en-
forcement efforts should accompany the
implementation of such policies. Adminis-
trators should carefully monitor the med-
ical literature for clues of ghostwriting,
such as an acknowledgment of a medical
writer’s assistance in a peer-reviewed
journal article. When a medical writer is
thanked, this will be taken to mean that
they do not qualify for authorship, much
in the way that a copyeditor does not
receive a byline credit. At present, such
acknowledgments are suspected to mean
that the medical writer actually ghostwrote
the paper (Figure 1) [28], but the imple-
mentation of a stringent ghostwriting
policy will require strict accuracy on this
issue. When there is doubt, aggressive
investigative action should be taken. The
empirical findings of medical literature
are unlikely to change, but reports of
authorship would thus be honest and
transparent.
Figure 1. Acknowledging ghostwriters does not accurately reflect their authorship role. Modified from [14]. Used under a Creative
Commons license which permits the modification and re-use of intellectual content as long as it is properly acknowledged.
doi:10.1371/journal.pmed.1000230.g001
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has violated this policy, rapid disciplinary
action should result. Sanctions should
be equivalent to those used in cases of
plagiarism or falsification of data. When a
behavior poses a significant public health
risk, most governments punish such be-
havior vigorously. For instance, most
governments heavily penalize people who
drive an automobile while intoxicated; the
goal is to protect the public by deterring
the behavior. Similarly, it is hard to
envision a policy that protects the public
from ghostwriting without punishing the
behavior.
Ultimately, this policy requires only
that academic medical centers follow
the norms of science, as exemplified
by other departments of the university.
Honest and transparent reporting of
authorship has always been an essential
element of scientific communication.
We can think of no ethical or scientific
reason why this proposal should not be
adopted by every academic medical
center.
Conclusion
Medical ghostwriting is a threat to
public health which currently takes place
only due to the cooperation of researchers
employed at academic medical centers.
Although there is growing awareness of
the danger posed by medical ghostwriting,
we find that few academic medical centers
have public policies which prohibit this
behavior, and many of the existing policies
are ambiguous or ill-defined. We have
proposed an unambiguous policy which
defines participating in medical ghostwrit-
ing as academic misconduct akin to
plagiarism or falsifying data. By adopting
and enforcing this policy, academic med-
ical centers would adhere to the norms of
science followed across the rest of the
University, and would no longer facilitate
clandestine industry influence over the
peer-reviewed scientific literature. By pro-
hibiting medical ghostwriting, academic
medical centers have a rare opportunity-
to significantly reduce a major threat to
public health with the stroke of a pen.
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